Director's Dealing • Jan 27, 2020
Director's Dealing
Open in ViewerOpens in native device viewer
Directors' Dealings-Announcement pursuant to artikle 19 MAR transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
personal data: responsible party: name: Brigitte EDERER (natural person) ------------------------------------------------------------------------------- reason: reason: responsible party is a person with managerial responsibilities function: Member of an administrative or supervisory board ------------------------------------------------------------------------------- issuer information: name: Marinomed Biotech AG Legal Entity Identifier (LEI): 529900GN3B1EN80XF405 ------------------------------------------------------------------------------- information about deal: ISIN: ATMARINOMED6 description of the financial instrument: Share type: acquisition date: 23.01.2020; UTC+01:00 market: Vienna Stock Exchange AG, XWBO currency: Euro price volume EUR 97 150 shares total volume: 150 shares total price: EUR 14,550 average price: EUR 97 -------------------------------------------------------------------------------- Further inquiry note: Dr. Eva Prieschl-Grassauer Chief Scientific Officer, Marinomed Veterinärplatz 1, 1210 Vienna, Austria T +43 (0)1 250 77 4460 E-Mail: [email protected] http://www.marinomed.com
Roland Mayrl Managing Partner, Metrum Communications Bauernmarkt 10/19, 1010 Vienna, Austria T +43 (0) 1 504 69 87 331 E-Mail: [email protected] http://www.metrum.at
end of announcement euro adhoc
| issuer: | Marinomed Biotech AG |
|---|---|
| Veterinärplatz 1 | |
| A-1210 Wien | |
| phone: | 0043250774460 |
| FAX: | 0043250774493 |
| mail: | [email protected] |
| WWW: | www.marinomed.com |
| ISIN: | ATMARINOMED6, AT0000A1WD52 |
| indexes: | |
| stockmarkets: Wien | |
| language: | English |
Aussendung übermittelt durch euro adhoc The European Investor Relations Service
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.